Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—shifting the paradigm

RJ Kurman, IM Shih - Human pathology, 2011‏ - Elsevier
Recent morphologic, immunohistochemical, and molecular genetic studies have led to the
development of a new paradigm for the pathogenesis and origin of epithelial ovarian cancer …

Recent progress in the diagnosis and treatment of ovarian cancer

D Jelovac, DK Armstrong - CA: a cancer journal for clinicians, 2011‏ - Wiley Online Library
Epithelial ovarian cancer is the most lethal of the gynecologic malignancies, largely due to
the advanced stage at diagnosis in most patients. Screening strategies using ultrasound and …

[HTML][HTML] Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

JA Ledermann, FA Raja, C Fotopoulou… - Annals of oncology, 2013‏ - Elsevier
The estimated number of new ovarian cancer cases in Europe in 2012 was 65 538 with 42
704 deaths [1]. There is variation in the incidence rate across the continent with a higher …

[ספר][B] Perez & Brady's principles and practice of radiation oncology

EC Halperin, LW Brady, CA Perez, DE Wazer - 2013‏ - books.google.com
Inside the Sixth Edition of this now-classic reference, you will discover encyclopedic
coverage of topics ranging from basic science to sophisticated computer-based radiation …

Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome

RW Tothill, AV Tinker, J George, R Brown… - Clinical cancer …, 2008‏ - aacrjournals.org
Purpose: The study aim to identify novel molecular subtypes of ovarian cancer by gene
expression profiling with linkage to clinical and pathologic features. Experimental Design …

Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation

M Vivinus-Nebot, G Frin-Mathy, H Bzioueche… - Gut, 2014‏ - gut.bmj.com
Objective To determine the role of colonic barrier defects and low-grade inflammation in
irritable bowel syndrome (IBS)-like symptoms in quiescent inflammatory bowel disease …

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study

J Farley, WE Brady, V Vathipadiekal, HA Lankes… - The lancet …, 2013‏ - thelancet.com
Background Low-grade serous carcinoma of the ovary is chemoresistant but mutations in
the MAPK pathway could be targeted to control tumour growth. We therefore assessed the …

Ovarian cancer

KR Cho, IM Shih - Annual review of pathology: mechanisms of …, 2009‏ - annualreviews.org
Ovarian carcinomas are a heterogeneous group of neoplasms and are traditionally
subclassified based on type and degree of differentiation. Although current clinical …

Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems

R Vang, IM Shih, RJ Kurman - Advances in anatomic pathology, 2009‏ - journals.lww.com
Ovarian serous carcinomas have been graded using various systems. Recently, a 2-tier
system in which tumors are subdivided into low grade and high grade has been proposed …

A mathematical-descriptor of tumor-mesoscopic-structure from computed-tomography images annotates prognostic-and molecular-phenotypes of epithelial ovarian …

H Lu, M Arshad, A Thornton, G Avesani… - Nature …, 2019‏ - nature.com
The five-year survival rate of epithelial ovarian cancer (EOC) is approximately 35–40%
despite maximal treatment efforts, highlighting a need for stratification biomarkers for …